CytomX(CTMX) - 2025 Q2 - Quarterly Results

Exhibit 99.1 CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) - - CX-2051 Phase 1 dose expansions on track for data update in Q1 2026. Phase 2 study initiation in CRC anticipated 1H 2026 - - Combination dose escalation initiated of CX-801 masked interferon alpha-2b with KEYTRUDA®(pembrolizu ...